Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1/2 6Phase 3 4Phase 1 3Phase NA 1Phase 4 1Phase 2/3 1

Status

Completed 3Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 24Genitourinary 8Head & Neck 4Gynecologic 4Thoracic 3Dermatologic 2Other hematologic neoplasm 1Endocrine 1

Conditions

Endometrial Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 1Advanced Endometrial Cancer 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 95Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × lenvatinib × Gynecologic × Clear all
NCT03517449 2026-03-19

MK-3475-775

Eisai Inc.

Phase 3 Completed
827 enrolled 34 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03884101 2026-02-02

LEAP-001

Merck Sharp & Dohme LLC

Phase 3 Completed
842 enrolled 25 charts
Gynecologic

Endometrial Neoplasms

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT04865289 2025-12-02

LEAP-001

Merck Sharp & Dohme LLC

Phase 3 Completed
130 enrolled 24 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡